BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 6283063)

  • 1. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.
    Endoh M; Yamashita S; Taira N
    J Pharmacol Exp Ther; 1982 Jun; 221(3):775-83. PubMed ID: 6283063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle.
    Endoh M; Yanagisawa T; Taira N; Blinks JR
    Circulation; 1986 Mar; 73(3 Pt 2):III117-33. PubMed ID: 2417745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the positive inotropic action of a novel cardiotonic agent, MCI-154, involve mechanisms other than cyclic AMP?
    Kitada Y; Narimatsu A; Suzuki R; Endoh M; Taira N
    J Pharmacol Exp Ther; 1987 Nov; 243(2):639-45. PubMed ID: 2824754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of effects of UK-1745, a novel cardiotonic agent with beta-adrenoceptor-blocking action, in aequorin-loaded canine right ventricular muscle.
    Sawada H; Endoh M
    J Mol Cell Cardiol; 1999 May; 31(5):1047-62. PubMed ID: 10336843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of sulmazole (AR-L 115 BS) on contractile force and cyclic AMP levels in canine ventricular muscle: comparison with MDL 17,043.
    Endoh M; Yanagisawa T; Morita T; Taira N
    J Pharmacol Exp Ther; 1985 Jul; 234(1):267-73. PubMed ID: 2989507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced relaxation and reduced positive inotropic effects of amrinone in ventricular muscle from cats with subacute heart failure. Implications for drug therapy.
    Bassett AL; Gaide MS; Lodge NJ; Cameron JS
    Adv Myocardiol; 1985; 6():629-36. PubMed ID: 2986264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
    Weishaar RE; Quade MM; Schenden JA; Evans DB
    J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inotropic effects of amrinone and milrinone on neonatal and young canine cardiac muscle.
    Binah O; Sodowick B; Vulliemoz Y; Danilo P; Rosen M
    Circulation; 1986 Mar; 73(3 Pt 2):III46-51. PubMed ID: 3002663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of cyclic AMP in the positive inotropic effect of OPC-8212, a new cardiotonic agent, on the canine ventricular muscle.
    Yanagisawa T; Endoh M; Taira N
    Jpn J Pharmacol; 1984 Nov; 36(3):379-88. PubMed ID: 6097725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-[imidazo (1,2-a) pyridin-6-yl]-3-pyridine carbonitrile hydrochloride monohydrate (E-1020) on contractile force and cyclic AMP metabolism in canine ventricular muscle.
    Satoh H; Endoh M
    Jpn J Pharmacol; 1990 Feb; 52(2):215-24. PubMed ID: 2156096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of the bipyridines: amrinone and milrinone.
    Alousi AA; Johnson DC
    Circulation; 1986 Mar; 73(3 Pt 2):III10-24. PubMed ID: 2417744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
    Ahn HS; Eardley D; Watkins R; Prioli N
    Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic GMP-dependent protein kinase activation in the absence of negative inotropic effects in the rat ventricle.
    MacDonell KL; Diamond J
    Br J Pharmacol; 1997 Dec; 122(7):1425-35. PubMed ID: 9421291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronotropic and inotropic actions of amrinone, carbazeran and isobutylmethyl xanthine: role of phosphodiesterase inhibition.
    Shahid M; Rodger IW
    Br J Pharmacol; 1989 Sep; 98(1):291-301. PubMed ID: 2478244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for the cardiovascular activities of amrinone and AR-L57.
    Hayes JS; Bowling N; Boder GB; Kauffman R
    J Pharmacol Exp Ther; 1984 Jul; 230(1):124-32. PubMed ID: 6086873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium.
    Endoh M; Shibasaki T; Satoh H; Norota I; Ishihata A
    J Cardiovasc Pharmacol; 1991 Mar; 17(3):365-75. PubMed ID: 1711596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a new 1,3-thiazole derivative ZSY-39 on force of contraction and cyclic AMP content in canine ventricular muscle.
    Endoh M; Satoh H; Norota I; Hirano K
    Cardiovasc Drugs Ther; 1990 Aug; 4(4):1127-34. PubMed ID: 1964579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect.
    Böhm M; Brückner R; Hackbarth I; Haubitz B; Linhart R; Meyer W; Schmidt B; Schmitz W; Scholz H
    J Pharmacol Exp Ther; 1984 Aug; 230(2):483-92. PubMed ID: 6086891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
    Price B; Pyne NJ; Houslay MD
    Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for opposing influences of cyclic GMP and cyclic AMP on force of contraction in mammalian myocardium.
    Nawrath H
    Recent Adv Stud Cardiac Struct Metab; 1976 May 26-29; 11():419-22. PubMed ID: 201992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.